Entering text into the input field will update the search result below

Synergy Pharmaceuticals' (SGYP) CEO Troy Hamilton on Q4 2017 Results - Earnings Call Transcript

SA Transcripts profile picture
SA Transcripts

Start Time: 16:30 January 1, 0000 5:03 PM ET

Synergy Pharmaceuticals, Inc. (NASDAQ:SGYP-OLD)

Q4 2017 Earnings Conference Call

March 01, 2018, 16:30 PM ET


Troy Hamilton - CEO

Gary Gemignani - CFO

Gem Hopkins - VP of IR and Corporate Communications


John Newman - Canaccord Genuity

Derek Archila - Oppenheimer

Liav Abraham - Citi


Greetings, and welcome to Synergy Pharmaceuticals Fourth Quarter and Full Year 2017 Webcast and Conference Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. [Operator Instructions]. As a reminder, this conference is being recorded.

I would now like to turn the conference over to Synergy’s Vice President of Investor Relations and Corporate Communications, Gem Hopkins.

Gem Hopkins

Good afternoon and thank you for joining us for the Synergy Pharmaceuticals fourth quarter and full year 2017 earnings call. During today's call, we will be walking through a slide presentation. If you haven't received the slide deck already, please make sure to visit the IR page of our corporate Web site at www.synergypharma.com to download a copy or follow along on the webcast.

I’d like to remind you that during the course of today's call, management will make projections or other forward-looking statements regarding anticipated future events or the future financial performance of the company. It's important to note that such statements and events are forward-looking and reflect our current perspective of the business trends and information as of today, Thursday, March 1, 2018.

Actual results may differ materially from current expectations and projections depending on a number of factors affecting the Synergy business. These factors are detailed in our periodic public filings with the Securities and Exchange Commission. Synergy disclaims any intent or obligation to update these forward-looking statements, except as expressly required by law.

Recommended For You

Comments (23)

Tumblebug profile picture
Need to vote against board member approval and against executtive compensation.
Lallemand profile picture
I did so today
UpagainDownagain profile picture
Imagine spending 30mil a year to gross 2mil a year => great pay for deadbeat management and a royal shearing of investor sheep.
ckarabin profile picture
People really do not understand the pharma business! They want to analyze it on a basis of current P&L, which is wrong. Instead, this is a business of spending money to acquire patients and once you get one, he's really yours for a long, long time, like an annuity stream. So you may pay say $5,000 upfront to get a patient, who then may provide you with an annual revenue stream of $5,000 per year for the next 10 years or more. Sure they lose $5,000 in year one and it looks terrible. But then it is all profit after that. Keep adding patients at attractive financial rates and eventually the "purchased annuities" start to add up and accumulate.
The problem is that waiting for the banquet is not always the wisest thing. We might die of starvation in the meantime. Remember Keynes?
moderena profile picture
The statement by management that they will not attempt to market their drug outside the USA is very encouraging. Most of us invested in this company due to the superiority of this new drug to the competition. The potential market is huge but it is a very competitive marketplace.

If a company with deep pockets and a large in place sales force acquires the right to the drug in China or Europe or Japan, etc then there is a lot of potential for explosive growth.

I understand the apprehension about further dilution and I wish they had addressed these concerns. Management has screwed the stockholders repeatedly. I bought around 5 so at this point I am hoping to at least recoup some of my losses. Another tough lesson learned to pay more attention to the quality of management.
petektf profile picture
maybe you should learn a different lesson, buy low. People who have a lower cost basis than you probably have a different perspective. Anyways, hold on tight, you may just get your wish.
welcome to keep shorting SGYP ,need some time to transfer money from other stocks.
Yeah good luck with that Gaojian. Keep us posted on your progress, or lack thereof.
bought a lot under 1.9
Mr Gemignani.... where exactly is the (VERY) slight reduction in cash burn coming from? Liav asked this question and what did he say/answer??? Gooble garble booble babble... duuuhh.
My goodness
Neals all they need to do is sign licensing agreements which they said they are willing to do. Probably in talks with more companies about X US options
petektf profile picture
Yea it seems like they're trying their best, just sit back and give them a little time to get things in order I guess.
This CEO is delivering what the previous one h ad failed. He has cut the. Expense, increased sales, getting insurance e coverage for this best in class drug and even more importantly, getting partnership to license the drug to pharmas internationally. SYGP is now on the right course in an able hand. No wonder shorts are worried and came out to bash. Will be conservatively a $5 stock. With partnership news to come anytime, so it can move up quickly
petektf profile picture
Most of the market is down today, but SGYP has a nice lil pop up with volume behind it. Well let's see what it's at, at the end of the day. =D
neals58 profile picture
That was one of,the worst calls I have ever seen. These guys are chumps and liars. More downside and a reverse split coming in 2019 along with dilution. 175-185 million in expenses in 2018 to drive what? Even a 100% increase would only give them 22-25 million. How many shares do they have to issue to get another 175K for 2019 AND repay the 200 Million which will definitely be in default by 2019. Jeez, will have 85% loss in this POC by year end.
Neal.....Amazon. By your take that stock would haven terrible for,the first six years. Always,the same with you.
Keeping an eye on SGYP
This guy Gary G needs to take a hike, deferred revenues??? How about the COGS???
ckarabin profile picture
It just takes time to build up a sales base for a new pharma product, but with their expanded indications and more insurance coverage now, they will continue to build out and gain revenue and cash flow. They do have a very effective product with less side effects, so it is just a matter of time
Vt divy&growth profile picture
hope so
1k shares at 3.50 would like to turn into a winner
Bought at much price (north of $5). so I hope this is will finally come in. So much positive have been written about it, but more recently, we have been hearing scary stories.

To report an error in this transcript, .Contact us to add your company to our coverage or use transcripts in your business. Learn more about Seeking Alpha transcripts here. Your feedback matters to us!

More on SGYP-OLD

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.